Suppr超能文献

中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对肝内胆管细胞癌患者的影响。

The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma.

机构信息

Erasmus MC University Medical Center, Rotterdam, Netherlands.

Ohio State University Wexner Medical Center, Columbus, OH.

出版信息

Surgery. 2018 Sep;164(3):411-418. doi: 10.1016/j.surg.2018.05.002. Epub 2018 Jun 11.

Abstract

BACKGROUND

Neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio may be host factors associated with prognosis. We sought to determine whether neutrophil-to-lymphocyte and platelets-to-lymphocyte ratio were associated with overall survival among patients undergoing surgery for intrahepatic cholangiocarcinoma.

METHODS

Patients who underwent resection for intrahepatic cholangiocarcinoma between 1990 and 2015 were identified from 12 major centers. Clinicopathologic factors and overall survival were compared among patients stratified by neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio. Risk factors identified on multivariable analysis were included in a prognostic model and the discrimination was assessed using Harrell's concordance index (C index).

RESULTS

A total of 991 patients were identified. Median neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio were 2.7 (interquartile range [IQR]: 2.0-4.0) and 109.6 (IQR: 72.4-158.8), respectively. Preoperative neutrophil-to-lymphocyte ratio was elevated (≥5) in 100 patients (10.0%) and preoperative platelets-to-lymphocyte ratio (≥190) in 94 patients (15.2%). Patients with low and high neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio generally had similar baseline characteristics with regard to tumor characteristics. Overall survival was 37.7 months (95% confidence interval [CI]: 32.7-42.6); 1-, 3-, and 5-year overall survival was 78.8%, 51.6%, and 39.3%, respectively. Patients with an neutrophil-to-lymphocyte ratio <5 had a median survival of 47.1 months (95% CI: 37.9-53.3) compared with a median survival of 21.9 months (95% CI: 4.8-39.1) among patients with an neutrophil-to-lymphocyte ratio ≥5 (P = .001). In contrast, patients who had a platelets-to-lymphocyte ratio <190 vs platelets-to-lymphocyte ratio ≥190 had comparable long-term survival (P > .05). On multivariable analysis, an elevated neutrophil-to-lymphocyte ratio was independently associated with decreased overall survival (hazard ratio: 1.04, 95% CI: 1.01-1.07; P = .002). Patients could be stratified into low- versus high-risk groups based on standard tumor-specific factors such as lymph node status, tumor size, number, and vascular invasion (C index 0.62). When neutrophil-to-lymphocyte ratio was added to the prognostic model, the discriminatory ability of the model improved (C index 0.71).

CONCLUSION

Elevated neutrophil-to-lymphocyte ratio was independently associated with worse overall survival and improved the prognostic estimation of long-term survival among patients with intrahepatic cholangiocarcinoma undergoing resection.

摘要

背景

中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值可能是与预后相关的宿主因素。我们旨在确定中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值是否与行肝内胆管癌切除术患者的总生存率相关。

方法

从 12 个主要中心确定了 1990 年至 2015 年期间接受肝内胆管癌切除术的患者。对按中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值分层的患者进行比较,评估临床病理因素和总生存率。多变量分析确定的危险因素被纳入预后模型,并使用 Harrell 的一致性指数(C 指数)评估其判别能力。

结果

共确定了 991 例患者。中位中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值分别为 2.7(四分位距 [IQR]:2.0-4.0)和 109.6(IQR:72.4-158.8)。100 例患者(10.0%)术前中性粒细胞与淋巴细胞比值升高(≥5),94 例患者(15.2%)术前血小板与淋巴细胞比值升高(≥190)。低和高中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值的患者在肿瘤特征方面的基线特征通常相似。总生存率为 37.7 个月(95%置信区间 [CI]:32.7-42.6);1、3 和 5 年总生存率分别为 78.8%、51.6%和 39.3%。中性粒细胞与淋巴细胞比值<5 的患者中位生存期为 47.1 个月(95%CI:37.9-53.3),而中性粒细胞与淋巴细胞比值≥5 的患者中位生存期为 21.9 个月(95%CI:4.8-39.1)(P=.001)。相比之下,血小板与淋巴细胞比值<190 与血小板与淋巴细胞比值≥190 的患者具有可比的长期生存率(P>.05)。多变量分析显示,升高的中性粒细胞与淋巴细胞比值与总生存率降低独立相关(风险比:1.04,95%CI:1.01-1.07;P=.002)。基于淋巴结状态、肿瘤大小、数量和血管侵犯等标准肿瘤特异性因素,患者可分为低危与高危组(C 指数 0.62)。当将中性粒细胞与淋巴细胞比值添加到预后模型中时,模型的判别能力得到改善(C 指数 0.71)。

结论

升高的中性粒细胞与淋巴细胞比值与肝内胆管癌切除术后患者的总生存率较差独立相关,并提高了对长期生存预后的估计。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验